<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03071861</url>
  </required_header>
  <id_info>
    <org_study_id>MEND 16-330</org_study_id>
    <nct_id>NCT03071861</nct_id>
  </id_info>
  <brief_title>Mild Encephalopathy in the Newborn Treated With Darbepoetin</brief_title>
  <acronym>MEND</acronym>
  <official_title>Mild Encephalopathy in the Newborn Treated With Darbepoetin (MEND)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of New Mexico</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Utah</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of New Mexico</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase II multicenter placebo-controlled randomized, feasibility/safety trial.
      Infants &gt;34 week gestational age with perinatal acidemia and mild neonatal encephalopathy on
      the modified Sarnat neurologic examination at less than six hours of age. Participants will
      be randomized to receive either one dose of Darbepoetin, or placebo within 24 hours of birth.
      Neurodevelopmental testing (Bayley III and Gross Motor Function Assessment) will be performed
      at 12-18 months of age.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Therapeutic hypothermia (TH) is the standard of care for newborns diagnosed with moderate to
      severe neonatal encephalopathy (NE) presumably due to hypoxic ischemia. In order to be
      eligible for TH an infant must have perinatal acidemia and evidence of moderate or severe
      encephalopathy on a standardized neurologic examination (Sarnat). However, the majority of
      newborns with perinatal acidemia do not have a neurologic examination abnormal enough to be
      classified as moderate or severe NE. In a retrospective review, DuPont et al. found that as
      many as 20% of newborns with perinatal academia and mild NE have abnormal short-term outcomes
      such as seizures, death from progressive asphyxia insult, brain MRI findings consistent with
      NE, abnormal neurologic examination at discharge, gastrostomy tube feeding, or feeding
      difficulties. Preliminary data from a prospective trial investigating mild NE (PRIME study,
      NCT01747863) found that 39% had either abnormal electroencephalography at &lt; 9h of age, an
      abnormal brain MRI finding, or abnormal neurological exam at discharge. Murray et al.
      recently reported on 5-year outcomes of infants with mild encephalopathy and showed that 25%
      had neurodevelopmental disability. These data suggest that mild NE likely carries a higher
      risk of impaired neurological outcome then reported previously. Thus it would appear that
      neuroprotective strategies would be beneficial in this group of infants. Preliminary data
      suggest that erythropoiesis stimulating agents (ESA) provide neuroprotection, and improve
      short and long-term neurologic outcome in neonatal brain injury. ESA may work through several
      mechanisms including reduced inflammation, limited oxidative stress, decreased apoptosis and
      white matter injury, as well as via pro-angiogenic and neurogenic properties. Darbepoetin
      alfa (Darbe), a recombinant human erythropoietin (EPO)-derived molecule has established
      safety and pharmacokinetics in newborns. Because Darbe has an extended circulating half-life
      with comparable biological activity to EPO, it has the advantage of requiring less frequent
      administration
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 1, 2017</start_date>
  <completion_date type="Anticipated">October 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Neurodevelopmental outcome</measure>
    <time_frame>12-18 months of age</time_frame>
    <description>Bayley III and Gross Motor Function Assessment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent of infants with adverse events</measure>
    <time_frame>30 days or until hospital discharge whichever comes first</time_frame>
    <description>Potential adverse events such as (but not limited to) alterations in blood pressure, secondary infections, neutropenia, thrombotic/vascular events, hematologic events (platelets, Hct level, polycythemia), and hepatic/renal function that are outside of normal range for the study population.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of infants with seizures</measure>
    <time_frame>30 days or until hospital discharge whichever comes first</time_frame>
    <description>development of clinical or electrographic seizures</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of infants who need gavage feeds or gastrostomy at discharge home</measure>
    <time_frame>30 days or until hospital discharge whichever comes first</time_frame>
    <description>Infants who require tube feedings at discharge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ages and Stages questionaire</measure>
    <time_frame>4-12 months of age</time_frame>
    <description>developmental screening test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Height measurment</measure>
    <time_frame>18-22 months of age</time_frame>
    <description>measured in cm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>weight measurement</measure>
    <time_frame>18-22 months of age</time_frame>
    <description>measured in kg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Head Circumference measurement</measure>
    <time_frame>18-22 months of age</time_frame>
    <description>measured in cm</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Percent with seizures</measure>
    <time_frame>4-12 months of age</time_frame>
    <description>development of clinical or electrographic seizures</description>
  </other_outcome>
  <other_outcome>
    <measure>Percent with Failure to Thrive</measure>
    <time_frame>4-12 months of age</time_frame>
    <description>Growth at &lt;3%</description>
  </other_outcome>
  <other_outcome>
    <measure>percent using early intervention services</measure>
    <time_frame>4-22 months of age</time_frame>
    <description>child is enrolled in an early intervention program</description>
  </other_outcome>
  <other_outcome>
    <measure>Percent with hearing impairment</measure>
    <time_frame>18-22 months of age</time_frame>
    <description>Child requires a hearing device</description>
  </other_outcome>
  <other_outcome>
    <measure>Percent with vision impairment</measure>
    <time_frame>18-22 months of age</time_frame>
    <description>requires corrective lenses</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Neonatal Encephalopathy</condition>
  <condition>Hypoxic-Ischemic Encephalopathy Mild</condition>
  <arm_group>
    <arm_group_label>Darbepoetin Alpha</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IV,10 mcg/kg/dose, Darbepoetin Alpha, one dose at &lt;24 hours of age</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>IV, Normal saline (placebo dose), one dose at &lt;24 hours of age</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Darbepoetin Alfa</intervention_name>
    <description>Single dose of 10 mcg/kg Darbepoetin Alpha given IV at less than 24 hours of age</description>
    <arm_group_label>Darbepoetin Alpha</arm_group_label>
    <other_name>Darbe</other_name>
    <other_name>Darbepoetin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal Saline</intervention_name>
    <description>Single dose of normal saline, IV, given at less than 24 hours of age</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria: Infants will be eligible for the MEND trial if they have a gestational
        age &gt; 34 weeks by best obstetric estimate, are &lt;24 hours old and have evidence of mild
        encephalopathy as defined by Shankaran et al based on a modified Sarnat examination
        performed at &lt;6 hours of age.

          1. History of an acute perinatal event (abruption, cord prolapsed, severe fetal heart
             rate abnormality, or meconium staining)

          2. Infant is evaluated for hypothermia therapy and DOES NOT meet clinical criteria for
             TH.

          3. Infant has an IV for clinical treatment

        Exclusion Criteria:

          1. Moderate/Severe encephalopathy on modified Sarnat examination at &lt; 6 hours of age

          2. Major congenital and/or chromosomal abnormalities

          3. Prenatal diagnosis of brain abnormality or hydrocephalus

          4. Severe growth restriction (&lt; 1800g)

          5. Central venous hematocrit &gt;65%, platelet count &gt;600,000/dL, and/or neutropenia
             (ANC&lt;500 Î¼L)

          6. Maternal history of major vascular thrombosis or multiple fetal losses (&gt; 3
             spontaneous abortions)

          7. ECMO

          8. Infant judged critically ill and unlikely to benefit from neonatal intensive care by
             the attending neonatologist
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>24 Hours</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John Philips, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of New Mexico</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tara L DuPont, MD</last_name>
    <phone>5052720180</phone>
    <email>tldupont@salud.unm.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Robin Ohls, MD</last_name>
    <phone>5052720180</phone>
    <email>rohls@salud.unm.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UNM Children's Hospital</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87131</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tara L DuPont, MD</last_name>
      <phone>505-272-0180</phone>
      <email>tldupont@salud.unm.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84108</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mariana Baserga, MD</last_name>
      <phone>801-587-7510</phone>
      <email>mariana.baserga@hsc.utah.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 1, 2016</study_first_submitted>
  <study_first_submitted_qc>March 1, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 7, 2017</study_first_posted>
  <last_update_submitted>January 8, 2018</last_update_submitted>
  <last_update_submitted_qc>January 8, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>darbepoetin</keyword>
  <keyword>Brain Diseases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Diseases</mesh_term>
    <mesh_term>Brain Ischemia</mesh_term>
    <mesh_term>Hypoxia-Ischemia, Brain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Darbepoetin alfa</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

